許 雅婷

Medicine & Life Sciences

1. T-Cell Lymphoma 67%
2. Drug Therapy 58%
3. ADI PEG20 37%
4. Lymphoma, Large B-Cell, Diffuse 32%
5. Vaccines 32%
6. Acquired Factor 8 deficiency 32%
7. Stromal Interaction Molecule 1 31%
8. Vaccination 30%
9. Survival 29%
10. SARS Virus 28%
11. Neoplasms 28%
12. Lymphoproliferative Disorders 26%
13. Thrombotic Thrombocytopenic Purpura 25%
14. Artificial Intelligence 25%
15. Human Herpesvirus 8 24%
16. Tight Junction Proteins 24%
17. Coronavirus 24%
18. Cytarabine 24%
19. Sarcopenia 24%
20. Thymoma 23%
21. Aplastic Anaemia 23%
22. Mutation 23%
23. Kaposi's Sarcoma 22%
24. Lymphoma 22%
25. Hematologic Diseases 22%
26. Herpesviridae 22%
27. Second Primary Neoplasms 22%
28. Factor VIII 21%
29. Frozen Sections 21%
30. Stem Cell Transplantation 20%
31. B-Cell Lymphoma 20%
32. Endometrial Neoplasms 19%
33. Therapeutics 19%
34. Ascites 19%
35. Precursor Cell Lymphoblastic Leukemia-Lymphoma 18%
36. Microtubules 18%
37. Transplant Recipients 17%
38. Multicenter Studies 16%